{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:16:45Z","timestamp":1790216205388,"version":"4.1.0"},"reference-count":147,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Due to the three domains of the colchicine-site which is conducive to the combination\nwith small molecule compounds, colchicine-site on the tubulin has become a common target for\nantitumor drug development, and accordingly, a large number of tubulin inhibitors binding to the\ncolchicine-site have been reported and evaluated over the past years. In this study, tubulin inhibitors\ntargeting the colchicine-site and their application as antitumor agents were reviewed based on the\nliterature from 2015 to 2019. Tubulin inhibitors were classified into ten categories according to the\nstructural features, including colchicine derivatives, CA-4 analogs, chalcone analogs, coumarin analogs,\nindole hybrids, quinoline and quinazoline analogs, lignan and podophyllotoxin derivatives,\nphenothiazine analogs, N-heterocycle hybrids and others. Most of them displayed potent antitumor\nactivity, including antiproliferative effects against Multi-Drug-Resistant (MDR) cell lines and antivascular\nproperties, both in vitro and in vivo. In this review, the design, synthesis and the analysis of\nthe structure-activity relationship of tubulin inhibitors targeting the colchicine-site were described in\ndetail. In addition, multi-target inhibitors, anti-MDR compounds, and inhibitors bearing antitumor\nactivity in vivo are further listed in tables to present a clear picture of potent tubulin inhibitors, which\ncould be beneficial for medicinal chemistry researchers.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867326666191003154051","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T14:10:07Z","timestamp":1570111807000},"page":"6787-6814","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Tubulin Inhibitors Binding to Colchicine-Site: A Review from 2015 to 2019"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1408-3305","authenticated-orcid":true,"given":"Lin-Ying","family":"Xia","sequence":"first","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-0676","authenticated-orcid":true,"given":"Ya-Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8252-8930","authenticated-orcid":true,"given":"Rong","family":"Yang","sequence":"additional","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1520-3751","authenticated-orcid":true,"given":"Zhong-Chang","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4483-3982","authenticated-orcid":true,"given":"Ya-Dong","family":"Lu","sequence":"additional","affiliation":[{"name":"Neonatal Medical Center, Children\u2019s Hospital of Nanjing Medical University, Nanjing 210008,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0861","authenticated-orcid":true,"given":"Bao-Zhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-7655","authenticated-orcid":true,"given":"Hai-Liang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Zhengzhou Children\u2019s Hospital, Zhengzhou 450018,China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/iub.25","volume":"60","author":"Pasquier E.","year":"2008","unstructured":"Pasquier E.; Kavallaris M.; Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008,60(3),165-170","journal-title":"IUBMB Life"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc1317","volume":"4","author":"Jordan M.A.","year":"2004","unstructured":"Jordan M.A.; Wilson L.; Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004,4(4),253-265","journal-title":"Nat Rev Cancer"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nrc2803","volume":"10","author":"Kavallaris M.","year":"2010","unstructured":"Kavallaris M.; Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010,10(3),194-204","journal-title":"Nat Rev Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"8722","DOI":"10.1038\/ncomms9722","volume":"6","author":"Chinen T.","year":"2015","unstructured":"Chinen T.; Liu P.; Shioda S.; Pagel J.; Cerikan B.; Lin T.C.; Gruss O.; Hayashi Y.; Takeno H.; Shima T.; Okada Y.; Hayakawa I.; Hayashi Y.; Kigoshi H.; Usui T.; Schiebel E.; The \u03b3-tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle. Nat Commun 2015,6(1),8722","journal-title":"Nat Commun"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fonc.2014.00153","volume":"4","author":"Parker A.L.","year":"2014","unstructured":"Parker A.L.; Kavallaris M.; McCarroll J.A.; Microtubules and their role in cellular stress in cancer. Front Oncol 2014,4,153","journal-title":"Front Oncol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/312237a0","volume":"312","author":"Mitchison T.","year":"1984","unstructured":"Mitchison T.; Kirschner M.; Mitchison T.K.M.; Dynamic instability of microtubule growth. Nature 1984,312(5991),237-242","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.cellbio.13.1.83","volume":"13","author":"Desai A.","year":"1997","unstructured":"Desai A.; Mitchison T.J.; Microtubule polymerization dynamics. Annu Rev Cell Dev Biol 1997,13(1),83-117","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ctrv.2008.11.001","volume":"35","author":"Risinger A.L.","year":"2009","unstructured":"Risinger A.L.; Giles F.J.; Mooberry S.L.; Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009,35(3),255-261","journal-title":"Cancer Treat Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrm4084","volume":"16","author":"Akhmanova A.","year":"2015","unstructured":"Akhmanova A.; Steinmetz M.O.; Control of microtubule organization and dynamics: two ends in the limelight. Nat Rev Mol Cell Biol 2015,16(12),711-726","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.4155\/fmc-2017-0100","volume":"9","author":"Li W.","year":"2017","unstructured":"Li W.; Sun H.; Xu S.; Zhu Z.; Xu J.; Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures. Future Med Chem 2017,9(15),1765-1794","journal-title":"Future Med Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"10298","DOI":"10.1038\/s41598-017-10972-0","volume":"7","author":"Lindamulage I.K.","year":"2017","unstructured":"Lindamulage I.K.; Vu H.Y.; Karthikeyan C.; Knockleby J.; Lee Y.F.; Trivedi P.; Lee H.; Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function. Sci Rep 2017,7(1),10298","journal-title":"Sci Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejps.2017.05.011","volume":"105","author":"Podolski-Reni\u0107 A.","year":"2017","unstructured":"Podolski-Reni\u0107 A.; Bankovi\u0107 J.; Dini\u0107 J.; R\u00edos-Luci C.; Fernandes M.X.; Ortega N.; Kova\u010devi\u0107-Gruji\u010di\u0107 N.; Mart\u00edn V.S.; Padr\u00f3n J.M.; Pe\u0161i\u0107 M.; DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Eur J Pharm Sci 2017,105,159-168","journal-title":"Eur J Pharm Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/0008-5472.CAN-17-0577","volume":"78","author":"Arnst K.E.","year":"2018","unstructured":"Arnst K.E.; Wang Y.; Hwang D-J.; Xue Y.; Costello T.; Hamilton D.; Chen Q.; Yang J.; Park F.; Dalton J.T.; Miller D.D.; Li W.; Potent A.A.; A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance. Cancer Res 2018,78(1),265-277","journal-title":"Cancer Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.canlet.2017.05.016","volume":"402","author":"Bai Z.","year":"2017","unstructured":"Bai Z.; Gao M.; Zhang H.; Guan Q.; Xu J.; Li Y.; Qi H.; Li Z.; Zuo D.; Zhang W.; Wu Y.; BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549\/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe. Cancer Lett 2017,402,81-92","journal-title":"Cancer Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejmech.2015.07.010","volume":"101","author":"Thakur A.","year":"2015","unstructured":"Thakur A.; Singla R.; Jaitak V.; Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies. Eur J Med Chem 2015,101,476-495","journal-title":"Eur J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejmech.2018.02.065","volume":"150","author":"Dadashpour S.","year":"2018","unstructured":"Dadashpour S.; Emami S.; Indole in the target-based design of anticancer agents: a versatile scaffold with diverse mechanisms. Eur J Med Chem 2018,150,9-29","journal-title":"Eur J Med Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1039\/C6NP00067C","volume":"33","author":"Jin Z.","year":"2016","unstructured":"Jin Z.; Muscarine, imidazole, oxazole and thiazole alkaloids. Nat Prod Rep 2016,33(11),1268-1317","journal-title":"Nat Prod Rep"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/molecules23010134","volume":"23","author":"Karrouchi K.","year":"2018","unstructured":"Karrouchi K.; Radi S.; Ramli Y.; Taoufik J.; Mabkhot Y.N.; Al-Aizari F.A.; Ansar M.; Synthesis and pharmacological activities of pyrazole derivatives: a review. Molecules 2018,23(1),134","journal-title":"Molecules"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejmech.2017.09.035","volume":"142","author":"Cascioferro S.","year":"2017","unstructured":"Cascioferro S.; Parrino B.; Span\u00f2 V.; Carbone A.; Montalbano A.; Barraja P.; Diana P.; Cirrincione G.; 1,3,5-triazines: a promising scaffold for anticancer drugs development. Eur J Med Chem 2017,142,523-549","journal-title":"Eur J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejmech.2015.07.037","volume":"102","author":"Singla P.","year":"2015","unstructured":"Singla P.; Luxami V.; Paul K.; Triazine as a promising scaffold for its versatile biological behavior. Eur J Med Chem 2015,102,39-57","journal-title":"Eur J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejmech.2014.09.051","volume":"87","author":"Kaur R.","year":"2014","unstructured":"Kaur R.; Kaur G.; Gill R.K.; Soni R.; Bariwal J.; Recent developments in tubulin polymerization inhibitors: an overview. Eur J Med Chem 2014,87,89-124","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ejmech.2014.09.089","volume":"97","author":"Briguglio I.","year":"2015","unstructured":"Briguglio I.; Piras S.; Corona P.; Gavini E.; Nieddu M.; Boatto G.; Carta A.; Benzotriazole: an overview on its versatile biological behavior. Eur J Med Chem 2015,97(1),612-648","journal-title":"Eur J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/ijms20061300","volume":"20","author":"Pieku\u015b-S\u0142omka N.","year":"2019","unstructured":"Pieku\u015b-S\u0142omka N.; Mikstacka R.; Ronowicz J.; Sobiak S.; Hybrid cis-stilbene molecules: novel anticancer agents. Int J Mol Sci 2019,20(6),1300","journal-title":"Int J Mol Sci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2174\/1871520616666160204111832","volume":"16","author":"Siebert A.","year":"2016","unstructured":"Siebert A.; Gensicka M.; Cholewinski G.; Dzierzbicka K.; Synthesis of combretastatin A-4 analogs and their biological activities. Anticancer Agents Med Chem 2016,16(8),942-960","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.15896","volume":"178","author":"Dasgeb B.","year":"2018","unstructured":"Dasgeb B.; Kornreich D.; McGuinn K.; Okon L.; Brownell I.; Sackett D.L.; Colchicine: an ancient drug with novel applications. Br J Dermatol 2018,178(2),350-356","journal-title":"Br J Dermatol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrrheum.2010.222","volume":"7","author":"Dalbeth N.","year":"2011","unstructured":"Dalbeth N.; Gout in 2010: progress and controversies in treatment. Nat Rev Rheumatol 2011,7(2),77-78","journal-title":"Nat Rev Rheumatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/15563650.2010.495348","volume":"48","author":"Finkelstein Y.","year":"2010","unstructured":"Finkelstein Y.; Aks S.E.; Hutson J.R.; Juurlink D.N.; Nguyen P.; Dubnov-Raz G.; Pollak U.; Koren G.; Bentur Y.; Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010,48(5),407-414","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/cells7110192","volume":"7","author":"Majcher U.","year":"2018","unstructured":"Majcher U.; Klejborowska G.; Moshari M.; Maj E.; Wietrzyk J.; Bartl F.; Tuszynski J.A.; Huczy\u0144ski A.; Antiproliferative activity and molecular docking of novel double-modified colchicine derivatives. Cells 2018,7(11),192","journal-title":"Cells"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bioorg.2018.09.004","volume":"81","author":"Majcher U.","year":"2018","unstructured":"Majcher U.; Urbaniak A.; Maj E.; Moshari M.; Delgado M.; Wietrzyk J.; Bartl F.; Chambers T.C.; Tuszynski J.A.; Huczy\u0144ski A.; Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes. Bioorg Chem 2018,81,553-566","journal-title":"Bioorg Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/cells7110216","volume":"7","author":"Majcher U.","year":"2018","unstructured":"Majcher U.; Klejborowska G.; Kaik M.; Maj E.; Wietrzyk J.; Moshari M.; Preto J.; Tuszynski J.; Huczy\u0144ski A.; Synthesis and biological evaluation of novel triple-modified colchicine derivatives as potent tubulin-targeting anticancer agents. Cells 2018,7(11),216","journal-title":"Cells"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/ph11010022","volume":"11","author":"Gentile F.","year":"2018","unstructured":"Gentile F.; Deriu M.A.; Barakat K.; Danani A.; Tuszynski J.; A novel interaction between the tlr7 and a colchicine derivative revealed through a computational and experimental study. Pharmaceuticals (Basel) 2018,11(1),22","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejmech.2015.03.035","volume":"95","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Kong Y.; Zhang J.; Su M.; Zhou Y.; Zang Y.; Li J.; Chen Y.; Fang Y.; Zhang X.; Lu W.; Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors. Eur J Med Chem 2015,95,127-135","journal-title":"Eur J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.1039\/C5OB00406C","volume":"13","author":"Singh B.","year":"2015","unstructured":"Singh B.; Kumar A.; Joshi P.; Guru S.K.; Kumar S.; Wani Z.A.; Mahajan G.; Hussain A.; Qazi A.K.; Kumar A.; Bharate S.S.; Gupta B.D.; Sharma P.R.; Hamid A.; Saxena A.K.; Mondhe D.M.; Bhushan S.; Bharate S.B.; Vishwakarma R.A.; Colchicine derivatives with potent anticancer activity and reduced P-glycoprotein induction liability. Org Biomol Chem 2015,13(20),5674-5689","journal-title":"Org Biomol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"13121","DOI":"10.1007\/s13277-016-5160-5","volume":"37","author":"Kumar A.","year":"2016","unstructured":"Kumar A.; Singh B.; Mahajan G.; Sharma P.R.; Bharate S.B.; Mintoo M.J.; Mondhe D.M.; A novel colchicine-based microtubule inhibitor exhibits potent antitumor activity by inducing mitochondrial mediated apoptosis in MIA PaCa-2 pancreatic cancer cells. Tumour Biol 2016,37(10),13121-13136","journal-title":"Tumour Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/cbf.3166","volume":"34","author":"Kumar A.","year":"2016","unstructured":"Kumar A.; Singh B.; Sharma P.R.; Bharate S.B.; Saxena A.K.; Mondhe D.M.; A novel microtubule depolymerizing colchicine analogue triggers apoptosis and autophagy in HCT-116 colon cancer cells. Cell Biochem Funct 2016,34(2),69-81","journal-title":"Cell Biochem Funct"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1039\/C6MD00459H","volume":"7","author":"Herdman C.A.","year":"2016","unstructured":"Herdman C.A.; Strecker T.E.; Tanpure R.P.; Chen Z.; Winters A.; Gerberich J.; Liu L.; Hamel E.; Mason R.P.; Chaplin D.J.; Trawick M.L.; Pinney K.G.; Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. MedChemComm 2016,7(12),2418-2427","journal-title":"MedChemComm"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e2143","DOI":"10.1038\/cddis.2016.53","volume":"7","author":"Mu Y.","year":"2016","unstructured":"Mu Y.; Liu Y.; Xiang J.; Zhang Q.; Zhai S.; Russo D.P.; Zhu H.; Bai X.; Yan B.; From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitor. Cell Death Dis 2016,7(3),e2143-e2143","journal-title":"Cell Death Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1021\/jm010523x","volume":"45","author":"Wang L.","year":"2002","unstructured":"Wang L.; Woods K.W.; Li Q.; Barr K.J.; McCroskey R.W.; Hannick S.M.; Gherke L.; Credo R.B.; Hui Y-H.; Marsh K.; Warner R.; Lee J.Y.; Zielinski-Mozng N.; Frost D.; Rosenberg S.H.; Sham H.L.; Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002,45(8),1697-1711","journal-title":"J Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrc723","volume":"2","author":"Mann J.","year":"2002","unstructured":"Mann J.; Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2002,2(2),143-148","journal-title":"Nat Rev Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.bmc.2010.03.006","volume":"18","author":"Burja B.","year":"2010","unstructured":"Burja B.; \u010cimbora-Zovko T.; Tomi\u0107 S.; Jelusi\u0107 T.; Ko\u010devar M.; Polanc S.; Osmak M.; Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies. Bioorg Med Chem 2010,18(7),2375-2387","journal-title":"Bioorg Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"25387","DOI":"10.1038\/srep25387","volume":"6","author":"Duan Y.T.","year":"2016","unstructured":"Duan Y.T.; Man R.J.; Tang D.J.; Yao Y.F.; Tao X.X.; Yu C.; Liang X.Y.; Makawana J.A.; Zou M.J.; Wang Z.C.; Zhu H.L.; Design, synthesis and antitumor activity of novel link-bridge and B-ring modified combretastatin A-4 (CA-4) analogues as potent antitubulin agents. Sci Rep 2016,6(1),25387","journal-title":"Sci Rep"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40661-017-0058-5","volume":"5","author":"Grisham R.","year":"2018","unstructured":"Grisham R.; Ky B.; Tewari K.S.; Chaplin D.J.; Walker J.; Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events and hypertension management. Gynecol Oncol Res Pract 2018,5(1),1","journal-title":"Gynecol Oncol Res Pract"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.2147\/OTT.S109186","volume":"9","author":"Garon E.B.","year":"2016","unstructured":"Garon E.B.; Neidhart J.D.; Gabrail N.Y.; de Oliveira M.R.; Balkissoon J.; Kabbinavar F.; A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets Ther 2016,9,7275-7283","journal-title":"OncoTargets Ther"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1628","volume":"5","author":"Tozer G.M.","year":"2005","unstructured":"Tozer G.M.; Kanthou C.; Baguley B.C.; Disrupting tumour blood vessels. Nat Rev Cancer 2005,5(6),423-435","journal-title":"Nat Rev Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128710","volume":"10","author":"Xu Q.","year":"2015","unstructured":"Xu Q.; Qi H.; Sun M.; Zuo D.; Jiang X.; Wen Z.; Wang Z.; Wu Y.; Zhang W.; synthesis and biological evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative activity. PLoS One 2015,10(6)","journal-title":"PLoS One"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bmc.2013.01.013","volume":"21","author":"Yang W.","year":"2013","unstructured":"Yang W.; Hu Y.; Yang Y.S.; Zhang F.; Zhang Y.B.; Wang X.L.; Tang J.F.; Zhong W.Q.; Zhu H.L.; Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with\/without thiourea skeleton as anticancer agents. Bioorg Med Chem 2013,21(5),1050-1063","journal-title":"Bioorg Med Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1016\/j.bmc.2014.05.017","volume":"22","author":"Li Y.J.","year":"2014","unstructured":"Li Y.J.; Qin Y.J.; Makawana J.A.; Wang Y.T.; Zhang Y.Q.; Zhang Y.L.; Yang M.R.; Jiang A.Q.; Zhu H.L.; Synthesis, biological evaluation and molecular modeling of 1,3,4-thiadiazol-2-amide derivatives as novel antitubulin agents. Bioorg Med Chem 2014,22(15),4312-4322","journal-title":"Bioorg Med Chem"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"34653","DOI":"10.1038\/srep34653","volume":"6","author":"Thomas E.","year":"2016","unstructured":"Thomas E.; Gopalakrishnan V.; Hegde M.; Kumar S.; Karki S.S.; Raghavan S.C.; Choudhary B.; A novel resveratrol based tubulin inhibitor induces mitotic arrest and activates apoptosis in cancer cells. Sci Rep 2016,6(1),34653","journal-title":"Sci Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1021\/acs.bioconjchem.6b00353","volume":"27","author":"Huang X.","year":"2016","unstructured":"Huang X.; Huang R.; Gou S.; Wang Z.; Liao Z.; Wang H.; Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action. Bioconjug Chem 2016,27(9),2132-2148","journal-title":"Bioconjug Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1124\/jpet.115.226225","volume":"355","author":"Greene L.M.","year":"2015","unstructured":"Greene L.M.; Meegan M.J.; Zisterer D.M.; Combretastatins: more than just vascular targeting agents? J Pharmacol Exp Ther 2015,355(2),212-227","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.020","volume":"380","author":"Mao J.","year":"2016","unstructured":"Mao J.; Wang D.; Wang Z.; Tian W.; Li X.; Duan J.; Wang Y.; Yang H.; You L.; Cheng Y.; Bian J.; Chen Z.; Yang Y.; Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt\/\u03b2-catenin pathway. Cancer Lett 2016,380(1),134-143","journal-title":"Cancer Lett"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1021\/acsmedchemlett.6b00427","volume":"8","author":"Doura T.","year":"2017","unstructured":"Doura T.; Takahashi K.; Ogra Y.; Suzuki N.; Combretastatin A4-\u03b2-galactosyl conjugates for ovarian cancer prodrug monotherapy. ACS Med Chem Lett 2017,8(2),211-214","journal-title":"ACS Med Chem Lett"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1021\/acs.orglett.5b02262","volume":"17","author":"Engdahl A.J.","year":"2015","unstructured":"Engdahl A.J.; Torres E.A.; Lock S.E.; Engdahl T.B.; Mertz P.S.; Streu C.N.; Synthesis, characterization, and bioactivity of the photoisomerizable tubulin polymerization inhibitor azo-combretastatin A4. Org Lett 2015,17(18),4546-4549","journal-title":"Org Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"12788","DOI":"10.1038\/s41598-017-12912-4","volume":"7","author":"Fu D.J.","year":"2017","unstructured":"Fu D.J.; Fu L.; Liu Y.C.; Wang J.W.; Wang Y.Q.; Han B.K.; Li X.R.; Zhang C.; Li F.; Song J.; Zhao B.; Mao R.W.; Zhao R.H.; Zhang S.Y.; Zhang L.; Zhang Y.B.; Liu H.M.; Structure-activity relationship studies of \u03b2-lactam-azide analogues as orally active antitumor agents targeting the tubulin colchicine site. Sci Rep 2017,7(1),12788","journal-title":"Sci Rep"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1016\/j.bmc.2015.04.055","volume":"23","author":"Wang F.","year":"2015","unstructured":"Wang F.; Yang Z.; Liu Y.; Ma L.; Wu Y.; He L.; Shao M.; Yu K.; Wu W.; Pu Y.; Nie C.; Chen L.; Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity. Bioorg Med Chem 2015,23(13),3337-3350","journal-title":"Bioorg Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.bmcl.2015.04.028","volume":"25","author":"Yu K.","year":"2015","unstructured":"Yu K.; Li R.; Yang Z.; Wang F.; Wu W.; Wang X.; Nie C.; Chen L.; Discovery of a potent microtubule-targeting agent: synthesis and biological evaluation of water-soluble amino acid prodrug of combretastatin A-4 derivatives. Bioorg Med Chem Lett 2015,25(11),2302-2307","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejmech.2018.05.010","volume":"156","author":"Lai Q.","year":"2018","unstructured":"Lai Q.; Wang Y.; Wang R.; Lai W.; Tang L.; Tao Y.; Liu Y.; Zhang R.; Huang L.; Xiang H.; Zeng S.; Gou L.; Chen H.; Yao Y.; Yang J.; Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site. Eur J Med Chem 2018,156,162-179","journal-title":"Eur J Med Chem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.ejmech.2018.12.030","volume":"163","author":"Zhang Y.L.","year":"2019","unstructured":"Zhang Y.L.; Li B.Y.; Yang R.; Xia L.Y.; Fan A.L.; Chu Y.C.; Wang L.J.; Wang Z.C.; Jiang A.Q.; Zhu H.L.; A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe. Eur J Med Chem 2019,163,896-910","journal-title":"Eur J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.3390\/molecules23112883","volume":"23","author":"Zhang C.","year":"2018","unstructured":"Zhang C.; Zhang X.; Wang G.; Peng Y.; Zhang X.; Wu H.; Yu B.; Sun J.; Preclinical pharmacokinetics of C118P, a novel prodrug of microtubules inhibitor and its metabolite C118 in mice, rats, and dogs. Molecules 2018,23(11),2883","journal-title":"Molecules"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bioorg.2018.02.027","volume":"78","author":"Kumar B.","year":"2018","unstructured":"Kumar B.; Sharma P.; Gupta V.P.; Khullar M.; Singh S.; Dogra N.; Kumar V.; Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies. Bioorg Chem 2018,78,130-140","journal-title":"Bioorg Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1016\/j.bmcl.2016.06.044","volume":"26","author":"Ashraf M.","year":"2016","unstructured":"Ashraf M.; Shaik T.B.; Malik M.S.; Syed R.; Mallipeddi P.L.; Vardhan M.V.P.S.V.; Kamal A.; Design and synthesis of cis-restricted benzimidazole and benzothiazole mimics of combretastatin A-4 as antimitotic agents with apoptosis inducing ability. Bioorg Med Chem Lett 2016,26(18),4527-4535","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","volume":"61","author":"Lamaa D.","year":"2018","unstructured":"Lamaa D.; Lin H.P.; Zig L.; Bauvais C.; Bollot G.; Bignon J.; Levaique H.; Pamlard O.; Dubois J.; Ouaissi M.; Souce M.; Kasselouri A.; Saller F.; Borgel D.; Jayat-Vignoles C.; Al-Mouhammad H.; Feuillard J.; Benihoud K.; Alami M.; Hamze A.; Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4. J Med Chem 2018,61(15),6574-6591","journal-title":"J Med Chem"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ejmech.2017.11.055","volume":"143","author":"Naret T.","year":"2018","unstructured":"Naret T.; Bignon J.; Bernadat G.; Benchekroun M.; Levaique H.; Lenoir C.; Dubois J.; Pruvost A.; Saller F.; Borgel D.; Manoury B.; Leblais V.; Darrigrand R.; Apcher S.; Brion J.D.; Schmitt E.; Leroux F.R.; Alami M.; Hamze A.; A fluorine scan of a tubulin polymerization inhibitor isocombretastatin A-4: design, synthesis, molecular modelling, and biological evaluation. Eur J Med Chem 2018,143,473-490","journal-title":"Eur J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.jmedchem.7b00480","volume":"60","author":"Pang Y.","year":"2017","unstructured":"Pang Y.; An B.; Lou L.; Zhang J.; Yan J.; Huang L.; Li X.; Yin S.; Design, synthesis, and biological evaluation of novel selenium-containing isocombretastatins and phenstatins as antitumor agents. J Med Chem 2017,60(17),7300-7314","journal-title":"J Med Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.bioorg.2018.03.028","volume":"78","author":"Wang G.","year":"2018","unstructured":"Wang G.; Peng Z.; Zhang J.; Qiu J.; Xie Z.; Gong Z.; Synthesis, biological evaluation and molecular docking studies of aminochalcone derivatives as potential anticancer agents by targeting tubulin colchicine binding site. Bioorg Chem 2018,78,332-340","journal-title":"Bioorg Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.ejmech.2014.08.033","volume":"85","author":"Singh P.","year":"2014","unstructured":"Singh P.; Anand A.; Kumar V.; Recent developments in biological activities of chalcones: a mini review. Eur J Med Chem 2014,85,758-777","journal-title":"Eur J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1517\/13543776.2014.995627","volume":"25","author":"Matos M.J.","year":"2015","unstructured":"Matos M.J.; Vazquez-Rodriguez S.; Uriarte E.; Santana L.; Potential pharmacological uses of chalcones: a patent review (from June 2011 - 2014). Expert Opin Ther Pat 2015,25(3),351-366","journal-title":"Expert Opin Ther Pat"},{"key":"ref=68","first-page":"422","volume":"13","author":"Sharma V.","year":"2013","unstructured":"Sharma V.; Kumar V.; Kumar P.; Heterocyclic chalcone analogues as potential anticancer agents. Anticancer Agents Med Chem 2013,13(3),422-432","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"14669","DOI":"10.18632\/oncotarget.4144","volume":"6","author":"Martel-Frachet V.","year":"2015","unstructured":"Martel-Frachet V.; Keramidas M.; Nurisso A.; DeBonis S.; Rome C.; Coll J.L.; Boumendjel A.; Skoufias D.A.; Ronot X.; IPP51, a chalcone acting as a microtubule inhibitor with in vivo antitumor activity against bladder carcinoma. Oncotarget 2015,6(16),14669-14686","journal-title":"Oncotarget"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1021\/acs.jmedchem.6b00021","volume":"59","author":"Yan J.","year":"2016","unstructured":"Yan J.; Chen J.; Zhang S.; Hu J.; Huang L.; Li X.; Synthesis, evaluation and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J Med Chem 2016,59(11),5264-5283","journal-title":"J Med Chem"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00280-018-3726-1","volume":"83","author":"Du S.","year":"2019","unstructured":"Du S.; Sarver J.G.; Trabbic C.J.; Erhardt P.W.; Schroering A.; Maltese W.A.; 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability. Cancer Chemother Pharmacol 2019,83(2),237-254","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bioorg.2017.11.017","volume":"76","author":"Wang G.","year":"2018","unstructured":"Wang G.; Qiu J.; Xiao X.; Cao A.; Zhou F.; Synthesis, biological evaluation and molecular docking studies of a new series of chalcones containing naphthalene moiety as anticancer agents. Bioorg Chem 2018,76,249-257","journal-title":"Bioorg Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1248\/cpb.25.2392","volume":"25","author":"Sankawa U.","year":"1977","unstructured":"Sankawa U.; Ebizuka Y.; Miyazaki T.; Isomura Y.; Otsuka H.; Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo) 1977,25(9),2392-2395","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cmdc.201700001","volume":"12","author":"Qiu H.Y.","year":"2017","unstructured":"Qiu H.Y.; Wang F.; Wang X.; Sun W.X.; Qi J.L.; Pang Y.J.; Yang R.W.; Lu G.H.; Wang X.M.; Yang Y.H.; Design, synthesis, and biological evaluation of chalcone-containing shikonin derivatives as inhibitors of tubulin polymerization. ChemMedChem 2017,12(5),399-406","journal-title":"ChemMedChem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1016\/j.bmc.2017.07.031","volume":"25","author":"Shankaraiah N.","year":"2017","unstructured":"Shankaraiah N.; Nekkanti S.; Brahma U.R.; Praveen Kumar N.; Deshpande N.; Prasanna D.; Senwar K.R.; Jaya Lakshmi U.; Synthesis of different heterocycles-linked chalcone conjugates as cytotoxic agents and tubulin polymerization inhibitors. Bioorg Med Chem 2017,25(17),4805-4816","journal-title":"Bioorg Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10637-019-00737-z","volume":"37","author":"Yan W.","year":"2019","unstructured":"Yan W.; Xiangyu C.; Ya L.; Yu W.; Feng X.; An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent. Invest New Drugs 2019,37(4),784-790","journal-title":"Invest New Drugs"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000489983","volume":"47","author":"Yan W.","year":"2018","unstructured":"Yan W.; Yang T.; Yang J.; Wang T.; Yu Y.; Wang Y.; Chen Q.; Bai P.; Li D.; Ye H.; Qiu Q.; Zhou Y.; Hu Y.; Yang S.; Wei Y.; Li W.; Chen L.; SKLB060 reversibly binds to colchicine site of tubulin and possesses efficacy in multidrug-resistant cell lines. Cell Physiol Biochem 2018,47(2),489-504","journal-title":"Cell Physiol Biochem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bioorg.2018.12.024","volume":"85","author":"Luo G.","year":"2019","unstructured":"Luo G.; Tang Z.; Li X.; Hou Q.; Chen Y.; Lao K.; Xiang H.; 3, 9-di-O-substituted coumestrols incorporating basic amine side chains act as novel apoptosis inducers with improved pharmacological selectivity. Bioorg Chem 2019,85,140-151","journal-title":"Bioorg Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ejmech.2019.01.033","volume":"165","author":"Fu D.J.","year":"2019","unstructured":"Fu D.J.; Li P.; Wu B.W.; Cui X.X.; Zhao C.B.; Zhang S.Y.; Molecular diversity of trimethoxyphenyl-1,2,3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors. Eur J Med Chem 2019,165,309-322","journal-title":"Eur J Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.foodchem.2013.03.053","volume":"141","author":"Lee Y.H.","year":"2013","unstructured":"Lee Y.H.; Yuk H.J.; Park K.H.; Bae Y.S.; Coumestrol induces senescence through protein kinase CKII inhibition-mediated reactive oxygen species production in human breast cancer and colon cancer cells. Food Chem 2013,141(1),381-388","journal-title":"Food Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.canlet.2015.08.021","volume":"369","author":"Strecker T.E.","year":"2015","unstructured":"Strecker T.E.; Odutola S.O.; Lopez R.; Cooper M.S.; Tidmore J.K.; Charlton-Sevcik A.K.; Li L.; MacDonough M.T.; Hadimani M.B.; Ghatak A.; Liu L.; Chaplin D.J.; Mason R.P.; Pinney K.G.; Trawick M.L.; The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. Cancer Lett 2015,369(1),229-241","journal-title":"Cancer Lett"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.canlet.2015.08.021","volume":"35","author":"Yeh Y.Y.","year":"2017","unstructured":"Yeh Y.Y.; Liou J.P.; Lee Y.L.; Lin J.Y.C.; Huang H.M.; MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells. Invest New Drugs 2017,35(4),427-435","journal-title":"Invest New Drugs"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fphar.2018.00205","volume":"9","author":"Wu Y.W.","year":"2018","unstructured":"Wu Y.W.; Hsu K.C.; Lee H.Y.; Huang T.C.; Lin T.E.; Chen Y.L.; Sung T.Y.; Liou J.P.; Hwang-Verslues W.W.; Pan S.L.; HuangFu, W.C. A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo. Front Pharmacol 2018,9,205","journal-title":"Front Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ejmech.2016.09.056","volume":"125","author":"Yan J.","year":"2017","unstructured":"Yan J.; Hu J.; An B.; Huang L.; Li X.; Design, synthesis and biological evaluation of cyclic-indole derivatives as anti-tumor agents via the inhibition of tubulin polymerization. Eur J Med Chem 2017,125,663-675","journal-title":"Eur J Med Chem"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejmech.2018.04.042","volume":"152","author":"La Regina G.","year":"2018","unstructured":"La Regina G.; Bai R.; Coluccia A.; Naccarato V.; Famiglini V.; Nalli M.; Masci D.; Verrico A.; Rovella P.; Mazzoccoli C.; Da Pozzo E.; Cavallini C.; Martini C.; Vultaggio S.; Dondio G.; Varasi M.; Mercurio C.; Hamel E.; Lavia P.; Silvestri R.; New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors. Eur J Med Chem 2018,152,283-297","journal-title":"Eur J Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12929-018-0432-6","volume":"25","author":"Tsai I.T.","year":"2018","unstructured":"Tsai I.T.; Kuo C.C.; Liou J.P.; Chang J.Y.; Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Biomed Sci 2018,25(1),28","journal-title":"J Biomed Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bioorg.2018.12.015","volume":"85","author":"Li W.","year":"2019","unstructured":"Li W.; Sun H.; Xu F.; Shuai W.; Liu J.; Xu S.; Yao H.; Ma C.; Zhu Z.; Xu J.; Synthesis, molecular properties prediction and biological evaluation of indole-vinyl sulfone derivatives as novel tubulin polymerization inhibitors targeting the colchicine binding site. Bioorg Chem 2019,85,49-59","journal-title":"Bioorg Chem"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1021\/acsmedchemlett.5b00208","volume":"6","author":"Hwang D.J.","year":"2015","unstructured":"Hwang D.J.; Wang J.; Li W.; Miller D.D.; Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents. ACS Med Chem Lett 2015,6(9),993-997","journal-title":"ACS Med Chem Lett"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1021\/jm300564b","volume":"55","author":"Chen J.","year":"2012","unstructured":"Chen J.; Ahn S.; Wang J.; Lu Y.; Dalton J.T.; Miller D.D.; Li W.; Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem 2012,55(16),7285-7289","journal-title":"J Med Chem"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-018-1009-7","volume":"38","author":"Kashyap V.K.","year":"2019","unstructured":"Kashyap V.K.; Wang Q.; Setua S.; Nagesh P.K.B.; Chauhan N.; Kumari S.; Chowdhury P.; Miller D.D.; Yallapu M.M.; Li W.; Jaggi M.; Hafeez B.B.; Chauhan S.C.; Therapeutic efficacy of a novel \u03b2III\/\u03b2IV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res 2019,38(1),29","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1021\/acs.jmedchem.8b00827","volume":"61","author":"Wang Q.","year":"2018","unstructured":"Wang Q.; Arnst K.E.; Wang Y.; Kumar G.; Ma D.; Chen H.; Wu Z.; Yang J.; White S.W.; Miller D.D.; Li W.; Structural modification of the 3,4,5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities. J Med Chem 2018,61(17),7877-7891","journal-title":"J Med Chem"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/cbdd.12932","volume":"90","author":"Wang Y.T.","year":"2017","unstructured":"Wang Y.T.; Cai X.C.; Shi T.Q.; Zhang Y.L.; Wang Z.C.; Liu C.H.; Zhu H.L.; Synthesis, molecular docking and biological evaluation of 1-phenylsulphonyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as novel potential tubulin assembling inhibitors. Chem Biol Drug Des 2017,90(1),112-118","journal-title":"Chem Biol Drug Des"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.tiv.2017.04.019","volume":"42","author":"Zuo D.","year":"2017","unstructured":"Zuo D.; Jiang X.; Han M.; Shen J.; Lang B.; Guan Q.; Bai Z.; Han C.; Li Z.; Zhang W.; Wu Y.; Methyl 5-[(1H-indol-3-yl)selanyl]-1H-benzoimidazol-2-ylcarbamate (M-24), a novel tubulin inhibitor, causes G2\/M arrest and cell apoptosis by disrupting tubulin polymerization in human cervical and breast cancer cells. Toxicol in vitro 2017,42,139-149","journal-title":"Toxicol in vitro"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejps.2018.05.011","volume":"121","author":"Fan A.","year":"2018","unstructured":"Fan A.; Wei J.; Yang M.; Zhang Q.; Zhang Y.; Liu Q.; Li N.; Zhao D.; Lu Y.; Li J.; Zhao J.; Deng S.; Zhang B.; Zhu H.; Chen X.; Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice. Eur J Pharm Sci 2018,121,74-84","journal-title":"Eur J Pharm Sci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ejmech.2018.07.044","volume":"156","author":"Chen K.","year":"2018","unstructured":"Chen K.; Zhang Y.L.; Fan J.; Ma X.; Qin Y.J.; Zhu H.L.; Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: design, synthesis and evaluation. Eur J Med Chem 2018,156,722-737","journal-title":"Eur J Med Chem"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2018.07.029","volume":"81","author":"Naaz F.","year":"2018","unstructured":"Naaz F.; Preeti Pallavi M.C.; Shafi S.; Mulakayala N.; Shahar Yar M.; Sampath Kumar H.M.; 1,2,3-triazole tethered Indole-3-glyoxamide derivatives as multiple inhibitors of 5-LOX, COX-2 and tubulin: their anti-proliferative and anti-inflammatory activity. Bioorg Chem 2018,81,1-20","journal-title":"Bioorg Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/cbdd.12616","volume":"86","author":"Hu M.J.","year":"2015","unstructured":"Hu M.J.; Zhang B.; Yang H.K.; Liu Y.; Chen Y.R.; Ma T.Z.; Lu L.; You W.W.; Zhao P.L.; Design, synthesis and molecular docking studies of novel indole-pyrimidine hybrids as tubulin polymerization inhibitors. Chem Biol Drug Des 2015,86(6),1491-1500","journal-title":"Chem Biol Drug Des"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1021\/acs.jmedchem.5b00805","volume":"58","author":"Carta D.","year":"2015","unstructured":"Carta D.; Bortolozzi R.; Hamel E.; Basso G.; Moro S.; Viola G.; Ferlin M.G.; Novel 3-substituted 7-phenylpyrrolo[3,2-f]quinolin-9(6H)-ones as single entities with multitarget antiproliferative activity. J Med Chem 2015,58(20),7991-8010","journal-title":"J Med Chem"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ejmech.2018.11.070","volume":"163","author":"Li W.","year":"2019","unstructured":"Li W.; Shuai W.; Sun H.; Xu F.; Bi Y.; Xu J.; Ma C.; Yao H.; Zhu Z.; Xu S.; Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site. Eur J Med Chem 2019,163,428-442","journal-title":"Eur J Med Chem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ejmech.2017.04.078","volume":"136","author":"Tantak M.P.","year":"2017","unstructured":"Tantak M.P.; Klingler L.; Arun V.; Kumar A.; Sadana R.; Kumar D.; Design and synthesis of bis(indolyl) ketohydrazide-hydrazones: identification of potent and selective novel tubulin inhibitors. Eur J Med Chem 2017,136,184-194","journal-title":"Eur J Med Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1039\/C9CC00074G","volume":"55","author":"Barman S.","year":"2019","unstructured":"Barman S.; Das G.; Mondal P.; Pradhan K.; Jana B.; Bhunia D.; Saha A.; Kar C.; Ghosh S.; Tripodal molecular propellers perturb microtubule dynamics: indole acts as a blade and plays a crucial role in anticancer activity. Chem Commun (Camb) 2019,55(16),2356-2359","journal-title":"Chem Commun (Camb)"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00280-015-2765-0","volume":"75","author":"Chang L.C.","year":"2015","unstructured":"Chang L.C.; Yu Y.L.; Liu C.Y.; Cheng Y.Y.; Chou R.H.; Hsieh M.T.; Lin H.Y.; Hung H.Y.; Huang L.J.; Wu Y.C.; Kuo S.C.; The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1. Cancer Chemother Pharmacol 2015,75(6),1303-1315","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=103","first-page":"747","volume":"6","author":"Chang L.C.","year":"2016","unstructured":"Chang L.C.; Yu Y.L.; Hsieh M.T.; Wang S.H.; Chou R.H.; Huang W.C.; Lin H.Y.; Hung H.Y.; Huang L.J.; Kuo S.C.; A novel microtubule inhibitor, MT3-037, causes cancer cell apoptosis by inducing mitotic arrest and interfering with microtubule dynamics. Am J Cancer Res 2016,6(4),747-763","journal-title":"Am J Cancer Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejmech.2016.02.069","volume":"114","author":"Shobeiri N.","year":"2016","unstructured":"Shobeiri N.; Rashedi M.; Mosaffa F.; Zarghi A.; Ghandadi M.; Ghasemi A.; Ghodsi R.; Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors. Eur J Med Chem 2016,114,14-23","journal-title":"Eur J Med Chem"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"71782","DOI":"10.18632\/oncotarget.17710","volume":"8","author":"Guan F.","year":"2017","unstructured":"Guan F.; Ding R.; Zhang Q.; Chen W.; Li F.; Long L.; Li W.; Li L.; Yang D.; Xie L.; Yuan S.; Wang L.; WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects. Oncotarget 2017,8(42),71782-71796","journal-title":"Oncotarget"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1021\/ml5004684","volume":"6","author":"Kuroiwa K.","year":"2015","unstructured":"Kuroiwa K.; Ishii H.; Matsuno K.; Asai A.; Suzuki Y.; Synthesis and structure-activity relationship study of 1-phenyl-1-(quinazolin-4-yl)ethanols as anticancer agents. ACS Med Chem Lett 2015,6(3),287-291","journal-title":"ACS Med Chem Lett"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-17-0332","volume":"17","author":"Wang F.","year":"2018","unstructured":"Wang F.; Zheng L.; Yi Y.; Yang Z.; Qiu Q.; Wang X.; Yan W.; Bai P.; Yang J.; Li D.; Pei H.; Niu T.; Ye H.; Nie C.; Hu Y.; Yang S.; Wei Y.; Chen L.; SKLB-23bb, A HDAC6-selective inhibitor, exhibits superior and broad-spectrum antitumor activity via additionally targeting microtubules. Mol Cancer Ther 2018,17(4),763-775","journal-title":"Mol Cancer Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.bmcl.2018.04.026","volume":"28","author":"Xu S.","year":"2018","unstructured":"Xu S.; An B.; Li Y.; Luo X.; Li X.; Jia X.; Synthesis and evaluation of new 2-chloro-4-aminopyrimidine and 2,6-dimethyl-4-aminopyrimidine derivatives as tubulin polymerization inhibitors. Bioorg Med Chem Lett 2018,28(10),1769-1775","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bioorg.2018.10.027","volume":"83","author":"Li W.","year":"2019","unstructured":"Li W.; Yin Y.; Shuai W.; Xu F.; Yao H.; Liu J.; Cheng K.; Xu J.; Zhu Z.; Xu S.; Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain. Bioorg Chem 2019,83,380-390","journal-title":"Bioorg Chem"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/molecules23071699","volume":"23","author":"Zayed M.F.","year":"2018","unstructured":"Zayed M.F.; Rateb H.S.; Ahmed S.; Khaled O.A.; Ibrahim S.R.M.; Quinazolinone-amino acid hybrids as dual inhibitors of EGFR kinase and tubulin polymerization. Molecules 2018,23(7),1699","journal-title":"Molecules"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ejmech.2019.01.011","volume":"165","author":"Sonawane V.","year":"2019","unstructured":"Sonawane V.; Mohd Siddique M.U.; Jadav S.S.; Sinha B.N.; Jayaprakash V.; Chaudhuri B.; Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy. Eur J Med Chem 2019,165,115-132","journal-title":"Eur J Med Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1021\/np9800553","volume":"61","author":"Sy L.K.","year":"1998","unstructured":"Sy L.K.; Brown G.D.; Novel phenylpropanoids and lignans from Illicium verum. J Nat Prod 1998,61(8),987-992","journal-title":"J Nat Prod"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0031-9422(00)80428-8","volume":"23","author":"MacRae W.D.","year":"1984","unstructured":"MacRae W.D.; Towers G.H.N.; Biological activities of lignans. Phytochemistry 1984,23(6),1207-1220","journal-title":"Phytochemistry"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0304-3835(00)00499-7","volume":"158","author":"Takasaki M.","year":"2000","unstructured":"Takasaki M.; Konoshima T.; Komatsu K.; Tokuda H.; Nishino H.; Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa. Cancer Lett 2000,158(1),53-59","journal-title":"Cancer Lett"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/np980136z","volume":"61","author":"Charlton J.L.","year":"1998","unstructured":"Charlton J.L.; Antiviral activity of lignans. J Nat Prod 1998,61(11),1447-1451","journal-title":"J Nat Prod"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1023\/B:PHYT.0000045487.02836.32","volume":"2","author":"Umezawa T.","year":"2003","unstructured":"Umezawa T.; Diversity in lignan biosynthesis. Phytochem Rev 2003,2(3),371-390","journal-title":"Phytochem Rev"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1021\/acs.jnatprod.6b00893","volume":"80","author":"Williams R.B.","year":"2017","unstructured":"Williams R.B.; Martin S.M.; Lawrence J.A.; Norman V.L.; O\u2019Neil-Johnson M.; Eldridge G.R.; Starks C.M.; Isolation and identification of the novel tubulin polymerization inhibitor bifidenone. J Nat Prod 2017,80(3),616-624","journal-title":"J Nat Prod"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ygyno.2018.08.008]","volume":"151","author":"Mills K.A.","year":"2018","unstructured":"Mills K.A.; Roach S.T.; Quinn J.M.; Guo L.; Beck H.M.; Lomonosova E.; Ilivicky A.R.; Starks C.M.; Lawrence J.A.; Hagemann A.R.; McCourt C.; Thaker P.H.; Powell M.A.; Mutch D.G.; Fuh K.C.; SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecol Oncol 2018,151(2),337-344","journal-title":"Gynecol Oncol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1021\/acs.jmedchem.7b01644","volume":"61","author":"Huang Z.","year":"2018","unstructured":"Huang Z.; Williams R.B.; Martin S.M.; Lawrence J.A.; Norman V.L.; O\u2019Neil-Johnson M.; Harding J.; Mangette J.E.; Liu S.; Guzzo P.R.; Starks C.M.; Eldridge G.R.; Bifidenone: structure-activity relationship and advanced preclinical candidate. J Med Chem 2018,61(15),6736-6747","journal-title":"J Med Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.toxicon.2004.05.008","volume":"44","author":"Gordaliza M.","year":"2004","unstructured":"Gordaliza M.; Garc\u00eda P.A.; del Corral J.M.; Castro M.A.; G\u00f3mez-Zurita M.A.; Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 2004,44(4),441-459","journal-title":"Toxicon"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1016\/j.bmcl.2016.05.063","volume":"26","author":"Han H.W.","year":"2016","unstructured":"Han H.W.; Qiu H.Y.; Hu C.; Sun W.X.; Yang R.W.; Qi J.L.; Wang X.M.; Lu G.H.; Yang Y.H.; Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs. Bioorg Med Chem Lett 2016,26(14),3237-3242","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1016\/j.bmc.2016.09.063","volume":"24","author":"Moise I.M.","year":"2016","unstructured":"Moise I.M.; B\u00eecu E.; Dubois J.; Farce A.; Rigo B.; Ghinet A.; Methylene versus carbonyl bridge in the structure of new tubulin polymerization inhibitors with tricyclic A-rings. Bioorg Med Chem 2016,24(22),6021-6030","journal-title":"Bioorg Med Chem"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10637-018-0682-x","volume":"37","author":"Liu N.","year":"2019","unstructured":"Liu N.; Jin Z.; Zhang J.; Jin J.; Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells. Invest New Drugs 2019,37(1),188-198","journal-title":"Invest New Drugs"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1021\/acs.jmedchem.5b00035","volume":"58","author":"Minegishi H.","year":"2015","unstructured":"Minegishi H.; Futamura Y.; Fukashiro S.; Muroi M.; Kawatani M.; Osada H.; Nakamura H.; Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods. J Med Chem 2015,58(10),4230-4241","journal-title":"J Med Chem"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10637-019-00753-z","volume":"38","author":"Wu J.D.","year":"2020","unstructured":"Wu J.D.; Cui Y.J.; Zhou Y.G.; Tang L.Q.; Zhang C.M.; Liu Z.P.; Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties. Invest New Drugs 2020,38(1),29-38","journal-title":"Invest New Drugs"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/molecules24020279","volume":"24","author":"Cui Y.J.","year":"2019","unstructured":"Cui Y.J.; Tang L.Q.; Zhang C.M.; Liu Z.P.; Synthesis of novel pyrazole derivatives and their tumor cell growth inhibitory activity. Molecules 2019,24(2),279","journal-title":"Molecules"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejmech.2016.02.004","volume":"112","author":"An W.","year":"2016","unstructured":"An W.; Wang W.; Yu T.; Zhang Y.; Miao Z.; Meng T.; Shen J.; Discovery of novel 2-phenyl-imidazo[1,2-a]pyridine analogues targeting tubulin polymerization as antiproliferative agents. Eur J Med Chem 2016,112,367-372","journal-title":"Eur J Med Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"17120","DOI":"10.1038\/s41598-017-17449-0","volume":"7","author":"Wu Y.","year":"2017","unstructured":"Wu Y.; Feng D.; Gao M.; Wang Z.; Yan P.; Gu Z.; Guan Q.; Zuo D.; Bao K.; Sun J.; Wu Y.; Zhang W.; Design and synthesis of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-2H-1,2,3-triazole derivatives as colchicine binding site inhibitors. Sci Rep 2017,7(1),17120","journal-title":"Sci Rep"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.bmc.2016.12.010","volume":"25","author":"Subba Rao A.V.","year":"2017","unstructured":"Subba Rao A.V.; Swapna K.; Shaik S.P.; Lakshma Nayak V.; Srinivasa Reddy T.; Sunkari S.; Shaik T.B.; Bagul C.; Kamal A.; Synthesis and biological evaluation of cis-restricted triazole\/tetrazole mimics of combretastatin-benzothiazole hybrids as tubulin polymerization inhibitors and apoptosis inducers. Bioorg Med Chem 2017,25(3),977-999","journal-title":"Bioorg Med Chem"},{"key":"ref=130","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.201700518","volume":"15","author":"Ameri A.","year":"2018","unstructured":"Ameri A.; Khodarahmi G.; Forootanfar H.; Hassanzadeh F.; Hakimelahi G.H.; Hybrid pharmacophore design, molecular docking, synthesis, and biological evaluation of novel aldimine-type schiff base derivatives as tubulin polymerization inhibitor. Chem Biodivers 2018,15(3)","journal-title":"Chem Biodivers"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biocel.2019.02.004","volume":"110","author":"Narayanan S.","year":"2019","unstructured":"Narayanan S.; Gupta P.; Nazim U.; Ali M.; Karadkhelkar N.; Ahmad M.; Chen Z.S.; Anti-cancer effect of indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. Int J Biochem Cell Biol 2019,110,21-28","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1016\/j.bmc.2017.07.048","volume":"25","author":"Song M.Y.","year":"2017","unstructured":"Song M.Y.; Cao C.Y.; He Q.R.; Dong Q.M.; Li D.; Tang J.J.; Gao J.M.; Constructing novel dihydrofuran and dihydroisoxazole analogues of isocombretastatin-4 as tubulin polymerization inhibitors through [3+2] reactions. Bioorg Med Chem 2017,25(20),5290-5302","journal-title":"Bioorg Med Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1871520617666170419124702","volume":"18","author":"Ahsan M.J.","year":"2018","unstructured":"Ahsan M.J.; Choupra A.; Sharma R.K.; Jadav S.S.; Padmaja P.; Hassan M.Z.; Al-Tamimi A.B.S.; Geesi M.H.; Bakht M.A.; Rationale design, synthesis, cytotoxicity evaluation, and molecular docking studies of 1,3,4-oxadiazole analogues. Anticancer Agents Med Chem 2018,18(1),121-138","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09491-9","volume":"7","author":"Gilson P.","year":"2017","unstructured":"Gilson P.; Josa-Prado F.; Beauvineau C.; Naud-Martin D.; Vanwonterghem L.; Mahuteau-Betzer F.; Moreno A.; Falson P.; Lafanech\u00e8re L.; Frachet V.; Coll J.L.; Fernando D\u00edaz J.; Hurbin A.; Busser B.; Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties. Sci Rep 2017,7(1),1-14","journal-title":"Sci Rep"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1021\/acsmedchemlett.7b00022","volume":"8","author":"La Regina G.","year":"2017","unstructured":"La Regina G.; Bai R.; Coluccia A.; Famiglini V.; Passacantilli S.; Naccarato V.; Ortar G.; Mazzoccoli C.; Ruggieri V.; Agriesti F.; Piccoli C.; Tataranni T.; Nalli M.; Brancale A.; Vultaggio S.; Mercurio C.; Varasi M.; Saponaro C.; Sergio S.; Maffia M.; Coluccia A.M.L.; Hamel E.; Silvestri R.; 3-Aroyl-1,4-diarylpyrroles inhibit chronic myeloid leukemia cell growth through an interaction with tubulin. ACS Med Chem Lett 2017,8(5),521-526","journal-title":"ACS Med Chem Lett"},{"key":"ref=136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173311","volume":"12","author":"Sakchaisri K.","year":"2017","unstructured":"Sakchaisri K.; Kim S.O.; Hwang J.; Soung N.K.; Lee K.H.; Choi T.W.; Lee Y.; Park C.M.; Thimmegowda N.R.; Lee P.Y.; Shwetha B.; Srinivasrao G.; Pham T.T.H.; Jang J.H.; Yum H.W.; Surh Y.J.; Lee K.S.; Park H.; Kim S.J.; Kwon Y.T.; Ahn J.S.; Kim B.Y.; Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One 2017,12(3)","journal-title":"PLoS One"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"31472","DOI":"10.1038\/srep31472","volume":"6","author":"Zheng Y.B.","year":"2016","unstructured":"Zheng Y.B.; Gong J.H.; Liu X.J.; Wu S.Y.; Li Y.; Xu X.D.; Shang B.Y.; Zhou J.M.; Zhu Z.L.; Si S.Y.; Zhen Y.S.; A novel nitrobenzoate microtubule inhibitor that overcomes multidrug resistance exhibits antitumor activity. Sci Rep 2016,6(1),31472","journal-title":"Sci Rep"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1021\/acsmedchemlett.6b00483","volume":"8","author":"D\u00f6bber A.","year":"2017","unstructured":"D\u00f6bber A.; Phoa A.F.; Abbassi R.H.; Stringer B.W.; Day B.W.; Johns T.G.; Abadleh M.; Peifer C.; Munoz L.; Development and biological evaluation of a photoactivatable small molecule microtubule-targeting agent. ACS Med Chem Lett 2017,8(4),395-400","journal-title":"ACS Med Chem Lett"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1021\/jm501859j","volume":"58","author":"Nakagawa-Goto K.","year":"2015","unstructured":"Nakagawa-Goto K.; Oda A.; Hamel E.; Ohkoshi E.; Lee K.H.; Goto M.; Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring. J Med Chem 2015,58(5),2378-2389","journal-title":"J Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1016\/j.bmc.2016.09.026","volume":"24","author":"Hayakawa I.","year":"2016","unstructured":"Hayakawa I.; Shioda S.; Chinen T.; Hatanaka T.; Ebisu H.; Sakakura A.; Usui T.; Kigoshi H.; Discovery of O6-benzyl glaziovianin A, a potent cytotoxic substance and a potent inhibitor of \u03b1,\u03b2-tubulin polymerization. Bioorg Med Chem 2016,24(21),5639-5645","journal-title":"Bioorg Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1016\/j.bmcl.2018.10.037","volume":"28","author":"Luo Y.","year":"2018","unstructured":"Luo Y.; Zhou Y.; Song Y.; Chen G.; Wang Y.X.; Tian Y.; Fan W.W.; Yang Y.S.; Cheng T.; Zhu H.L.; Optimization of substituted cinnamic acyl sulfonamide derivatives as tubulin polymerization inhibitors with anticancer activity. Bioorg Med Chem Lett 2018,28(23-24),3634-3638","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/j.bmcl.2016.03.068","volume":"26","author":"Madadi N.R.","year":"2016","unstructured":"Madadi N.R.; Ketkar A.; Penthala N.R.; Bostian A.C.L.; Eoff R.L.; Crooks P.A.; Dioxol and dihydrodioxin analogs of 2- and 3-phenylacetonitriles as potent anti-cancer agents with nanomolar activity against a variety of human cancer cells. Bioorg Med Chem Lett 2016,26(9),2164-2169","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejmech.2017.12.019","volume":"144","author":"Lin H.Y.","year":"2018","unstructured":"Lin H.Y.; Han H.W.; Sun W.X.; Yang Y.S.; Tang C.Y.; Lu G.H.; Qi J.L.; Wang X.M.; Yang Y.H.; Design and characterization of \u03b1-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors. Eur J Med Chem 2018,144,137-150","journal-title":"Eur J Med Chem"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.bbrc.2017.10.104","volume":"495","author":"Cheng J.","year":"2018","unstructured":"Cheng J.; Wu Y.; Wang Y.; Wang C.; Wang Y.; Wu C.; Zeng S.; Yu Y.; Chen Q.; Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design. Biochem Biophys Res Commun 2018,495(1),185-188","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.bmc.2019.02.018","volume":"27","author":"Kaise A.","year":"2019","unstructured":"Kaise A.; Endo Y.; Ohta K.; Anti-cancer activity of M-carborane-containing trimethoxyphenyl derivatives through tubulin polymerization inhibition. Bioorg Med Chem 2019,27(6),1139-1144","journal-title":"Bioorg Med Chem"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"67017","DOI":"10.18632\/oncotarget.17549","volume":"8","author":"Kulshrestha A.","year":"2017","unstructured":"Kulshrestha A.; Katara G.K.; Ibrahim S.A.; Patil R.; Patil S.A.; Beaman K.D.; Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells. Oncotarget 2017,8(40),67017-67028","journal-title":"Oncotarget"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejmech.2015.03.005","volume":"94","author":"Parrino B.","year":"2015","unstructured":"Parrino B.; Carbone A.; Ciancimino C.; Span\u00f2 V.; Montalbano A.; Barraja P.; Cirrincione G.; Diana P.; Sissi C.; Palumbo M.; Pinato O.; Pennati M.; Beretta G.; Folini M.; Matyus P.; Balogh B.; Zaffaroni N.; Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action. Eur J Med Chem 2015,94,149-162","journal-title":"Eur J Med Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867326666191003154051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/175311\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867326666191003154051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T16:56:12Z","timestamp":1660582572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/175311\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":147,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666191003154051","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}